My view is that we are on the road and heading in the right direction.
Takeda is committed and is having outstanding success. With the European sales starting to pick up and a post market study out that would most probably support government reimbursements, the sales could increase 10 fold over night.
Some say the Japanese market is small. Small they may be however the therapy is covered by government. Manufacturing facility has only just been commissioned.
Sales must now be added to the value of MSB . A increase in royalties of between 1 and 2 million quarterly would I think be appropriate at this stage just from Japan .
US market is next on the agenda, and they are well on the way.
Good luck all.
Ann: Appendix 4C Quarterly Activity Report, page-28
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |